Skip to main content
NCBI home page
Epidemiology and Infection logoLink to Epidemiology and Infection
. 1988 Jun;100(3):335–344. doi: 10.1017/s095026880006708x

Immunogenicity of specific Bordetella pertussis surface antigens in diphtheria-tetanus-pertussis (DTP) vaccines.

A C Blaskett 1, J C Cox 1
PMCID: PMC2249346  PMID: 2897927

Abstract

The predominant causative organism of whooping cough in Australia is of a serotype which has normally been associated overseas with unvaccinated communities. Australian DTP vaccines pass the statutory mouse test for Bordetella pertussis potency but this test is now believed to be relatively insensitive to certain factors, especially the major type-specific agglutinogens, which are presumably also important in the human host-parasite relationship. Because endemic B. bronchiseptica infections make some laboratory animals unsatisfactory for testing B. pertussis agglutinin responses, we have developed a test in which young farm sheep were immunized with vaccines. Type-specific agglutinins in their sera were assayed after absorption of non-specific agglutinins by suspensions of selected bordetella strains. Three well-reputed European DTP vaccines and two recent batches of Australian DTP vaccine were tested and compared thus. All evoked significant agglutinin responses to the main agglutinogens.

Full text

PDF
335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agarwal K. C., Preston N. W. Pertussis agglutinins in vaccinated mice : difficulty in estimating the type-specific response. Indian J Med Res. 1976 Mar;64(3):393–398. [PubMed] [Google Scholar]
  2. Ashworth L. A., Fitzgeorge R. B., Irons L. I., Morgan C. P., Robinson A. Rabbit nasopharyngeal colonization by Bordetella pertussis: the effects of immunization on clearance and on serum and nasal antibody levels. J Hyg (Lond) 1982 Jun;88(3):475–486. doi: 10.1017/s0022172400070339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blaskett A. C., Gulasekharam J., Fulton L. C. The occurrence of Bordetella pertussis serotypes in Australia, 1950-1970. Med J Aust. 1971 Apr 10;1(15):781–784. doi: 10.5694/j.1326-5377.1971.tb87864.x. [DOI] [PubMed] [Google Scholar]
  4. Bronne-Shanbury C. J. The importance of agglutinin production in mice in the determination of the definitive serotype of Bordetella pertussis. J Hyg (Lond) 1976 Apr;76(2):257–264. doi: 10.1017/s0022172400055157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen S. M., Wheeler M. W. Pertussis Vaccine Prepared with Phase-I Cultures Grown in Fluid Medium. Am J Public Health Nations Health. 1946 Apr;36(4):371–376. [PMC free article] [PubMed] [Google Scholar]
  6. ELDERING G., HORNBECK C., BAKER J. Serological study of Bordetella pertussis and related species. J Bacteriol. 1957 Aug;74(2):133–136. doi: 10.1128/jb.74.2.133-136.1957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goodnow R. A. Biology of Bordetella bronchiseptica. Microbiol Rev. 1980 Dec;44(4):722–738. doi: 10.1128/mr.44.4.722-738.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Holt L. B. Pitfalls in the preparation of monotypic agglutinating antisera for Bordetella pertussis. J Med Microbiol. 1968 Nov;1(2):169–180. doi: 10.1099/00222615-1-2-169. [DOI] [PubMed] [Google Scholar]
  9. MAITLAND H. B., GUERAULT A. Some surface components of Haemophilus pertussis: immunising antigen, histamine-sensitising factor and agglutinogen. J Pathol Bacteriol. 1958 Jul;76(1):257–274. doi: 10.1002/path.1700760128. [DOI] [PubMed] [Google Scholar]
  10. PRESTON N. W., TE PUNGA W. A. The relation between agglutinin production by pertussis vaccines and their immunising potency in mice. J Pathol Bacteriol. 1959 Jul;78:209–216. doi: 10.1002/path.1700780123. [DOI] [PubMed] [Google Scholar]
  11. Preston N. W. Potency tests for pertussis vaccines: doubtful value of intracerebral challenge test in mice. J Pathol Bacteriol. 1966 Jan;91(1):173–179. doi: 10.1002/path.1700910121. [DOI] [PubMed] [Google Scholar]
  12. Preston N. W. Prevalent serotypes of Bordetella pertussis in non-vaccinated communities. J Hyg (Lond) 1976 Aug;77(1):85–91. doi: 10.1017/s0022172400055546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Preston N. W., Stanbridge T. N. Mouse or man? Which are pertussis vaccines to protect? J Hyg (Lond) 1976 Apr;76(2):249–256. doi: 10.1017/s0022172400055145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Preston N. W. Technical problems in the laboratory diagnosis and prevention of whooping-cough. Lab Pract. 1970 May;19(5):482–486. [PubMed] [Google Scholar]
  15. Robinson A., Irons L. I., Ashworth L. A. Pertussis vaccine: present status and future prospects. Vaccine. 1985 Mar;3(1):11–22. doi: 10.1016/0264-410x(85)90004-0. [DOI] [PubMed] [Google Scholar]
  16. Robinson A., Irons L. I. Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice. Infect Immun. 1983 May;40(2):523–528. doi: 10.1128/iai.40.2.523-528.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. de BOCK C., WORST-VAN DAM A. M. Fixation of the agglutinogen from Hemophilus pertussis on the bacterial surface. Antonie Van Leeuwenhoek. 1960;26:126–128. doi: 10.1007/BF02539000. [DOI] [PubMed] [Google Scholar]

Articles from Epidemiology and Infection are provided here courtesy of Cambridge University Press

RESOURCES